Document Type
Article
Publication Date
11-17-2023
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes.
Recommended Citation
Murthy, Hemant S.; Zhang, Mei-Jie; Chen, Karen; Ahmed, Sairah; Deotare, Uday; Ganguly, Siddhartha; Kansagra, Ankit; Michelis, Fotios V.; Nishihori, Taiga; Patnaik, Mrinal; Abid, Muhammad Bilal; Aljurf, Mahmoud; Arai, Yasuyuki; Bacher, Ulrike; Badar, Talha; Badawy, Sherif M.; Ballen, Karen; Battiwalla, Minoo; Beitinjaneh, Amer; Bejanyan, Nelli; Bhatt, Vijaya Raj; Brown, Valerie I.; Martino, Rodrigo; Cahn, Jean-Yves; Castillo, Paul; Cerny, Jan; Chhabra, Saurabh; Copelan, Edward; Daly, Andrew; Dholaria, Bhagirathbhai; Diaz Perez, Miguel Angel; Freytes, César O.; Grunwald, Michael R.; Hashmi, Shahrukh; Hildebrandt, Gerhard C.; Jamy, Omer; Joseph, Jacinth; Kanakry, Christopher G.; Khera, Nandita; Krem, Maxwell M.; Kuwatsuka, Yachiyo; Lazarus, Hillard M.; Lekakis, Lazaros J.; Liu, Hongtao; Modi, Dipenkumar; Munshi, Pashna N.; Mussetti, Alberto; Palmisiano, Neil D.; Patel, Sagar S.; Rizzieri, David A.; Seo, Sachiko; Shah, Mithun Vinod; Sharma, Akshay; Sohl, Melhm; Solomon, Scott R.; Ulrickson, Matthew; Ustun, Celalettin; van der Poel, Marjolein; Verdonck, Leo F.; Wagner, John L.; Wang, Trent; Wirk, Baldeep; Zeidan, Amer; Litzow, Mark; Kebriaei, Partow; Hourigan, Christopher S.; Weisdorf, Daniel J.; Saber, Wael; and Kharfan-Dabaja, Mohamed A., "Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A CIBMTR Analysis" (2023). Department of Medical Oncology Faculty Papers. Paper 257.
https://jdc.jefferson.edu/medoncfp/257
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
PubMed ID
37792849
Language
English
Comments
This article is the author's final published version in Blood Advances, Volume 7, Issue 22, 28 November 2023, Pg. 7007 - 7016.
The published version is available at https://doi.org/10.1182/bloodadvances.2023011308. Copyright © 2023 by American Society of Hematology.